Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Sergio Muñoz-Martínez; Victor Sapena; Alejandro Forner; Jean Charles Nault; Gonzalo Sapisochin; Lorenza Rimassa; Bruno Sangro; Jordi Bruix; Marco Sanduzzi-Zamparelli; Wacław Hołówko; Mohamed El Kassas; Tudor Mocan; Mohamed Bouattour; Philippe Merle; Frederik J.H. Hoogwater; Saleh A. Alqahtani; Helen L. Reeves; David J. Pinato; Emmanouil Giorgakis; Tim Meyer; Gerda Elisabeth Villadsen; Henning Wege; Massimiliano Salati; Beatriz Mínguez; Giovan Giuseppe Di Costanzo; Christoph Roderburg; Frank Tacke; María Varela; Peter R. Galle; Mario Reis Alvares-da-Silva; Jörg Trojan; John Bridgewater; Giuseppe Cabibbo; Christian Toso; Anja Lachenmayer; Andrea Casadei-Gardini; Hidenori Toyoda; Tom Lüdde; Rosanna Villani; Ana María Matilla Peña; Cassia Regina Guedes Leal; Monica Ronzoni; Manuel Delgado; Christie Perelló; Sonia Pascual; José Luis Lledó; Josepmaria Argemi; Bristi Basu; Leonardo da Fonseca; Juan Acevedo; Alexander R. Siebenhüner; Chiara Braconi; Brandon M. Meyers; Alessandro Granito; Margarita Sala; Carlos Rodríguez-Lope; Lorraine Blaise; Manuel Romero-Gómez; Federico Piñero; Dhanny Gomez; Vivianne Mello; Rogerio Camargo Pinheiro Alves; Alex França; Fernanda Branco; Giovanni Brandi; Gustavo Pereira; Susanna Coll; Maria Guarino; Carlos Benítez; Maria Margarita Anders; Juan C. Bandi; Mercedes Vergara; Mariona Calvo; Markus Peck-Radosavljevic; Ignacio García-Juárez; Vincenzo Cardinale; Mar Lozano; Martina Gambato; Stefano Okolicsanyi; Dalia Morales-Arraez; Alessandra Elvevi; Alberto E. Muñoz; Alberto Lué; Massimo Iavarone; Maria Reig

doi:10.1016/j.jhepr.2021.100260

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner, Jean Charles Nault, Gonzalo Sapisochin, Lorenza Rimassa, Bruno Sangro, Jordi Bruix, Marco Sanduzzi-Zamparelli, Wacław Hołówko, Mohamed El Kassas, Tudor Mocan, Mohamed Bouattour, Philippe Merle, Frederik J.H. Hoogwater, Saleh A. Alqahtani, Helen L. Reeves, David J. Pinato, Emmanouil Giorgakis, Tim MeyerGerda Elisabeth Villadsen, Henning Wege, Massimiliano Salati, Beatriz Mínguez, Giovan Giuseppe Di Costanzo, Christoph Roderburg, Frank Tacke, María Varela, Peter R. Galle, Mario Reis Alvares-da-Silva, Jörg Trojan, John Bridgewater, Giuseppe Cabibbo, Christian Toso, Anja Lachenmayer, Andrea Casadei-Gardini, Hidenori Toyoda, Tom Lüdde, Rosanna Villani, Ana María Matilla Peña, Cassia Regina Guedes Leal, Monica Ronzoni, Manuel Delgado, Christie Perelló, Sonia Pascual, José Luis Lledó, Josepmaria Argemi, Bristi Basu, Leonardo da Fonseca, Juan Acevedo, Alexander R. Siebenhüner, Chiara Braconi, Brandon M. Meyers, Alessandro Granito, Margarita Sala, Carlos Rodríguez-Lope, Lorraine Blaise, Manuel Romero-Gómez, Federico Piñero, Dhanny Gomez, Vivianne Mello, Rogerio Camargo Pinheiro Alves, Alex França, Fernanda Branco, Giovanni Brandi, Gustavo Pereira, Susanna Coll, Maria Guarino, Carlos Benítez, Maria Margarita Anders, Juan C. Bandi, Mercedes Vergara, Mariona Calvo, Markus Peck-Radosavljevic, Ignacio García-Juárez, Vincenzo Cardinale, Mar Lozano, Martina Gambato, Stefano Okolicsanyi, Dalia Morales-Arraez, Alessandra Elvevi, Alberto E. Muñoz, Alberto Lué, Massimo Iavarone, Maria Reig

Research output: Contribution to journal › Article › peer-review

Abstract

Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.

Original language	English (US)
Article number	100260
Journal	JHEP Reports
Volume	3
Issue number	3
DOIs	https://doi.org/10.1016/j.jhepr.2021.100260
State	Published - Jun 2021
Externally published	Yes

Keywords

COVID-19
Cholangiocarcinoma
Clinical trials
Hepatocellular carcinoma
Liver cancer
Management
Nurses

ASJC Scopus subject areas

Internal Medicine
Immunology and Allergy
Hepatology
Gastroenterology

Access to Document

10.1016/j.jhepr.2021.100260

Cite this

Muñoz-Martínez, S., Sapena, V., Forner, A., Nault, J. C., Sapisochin, G., Rimassa, L., Sangro, B., Bruix, J., Sanduzzi-Zamparelli, M., Hołówko, W., El Kassas, M., Mocan, T., Bouattour, M., Merle, P., Hoogwater, F. J. H., Alqahtani, S. A., Reeves, H. L., Pinato, D. J., Giorgakis, E., ... Reig, M. (2021). Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 3(3), Article 100260. https://doi.org/10.1016/j.jhepr.2021.100260

Muñoz-Martínez, S, Sapena, V, Forner, A, Nault, JC, Sapisochin, G, Rimassa, L, Sangro, B, Bruix, J, Sanduzzi-Zamparelli, M, Hołówko, W, El Kassas, M, Mocan, T, Bouattour, M, Merle, P, Hoogwater, FJH, Alqahtani, SA, Reeves, HL, Pinato, DJ, Giorgakis, E, Meyer, T, Villadsen, GE, Wege, H, Salati, M, Mínguez, B, Di Costanzo, GG, Roderburg, C, Tacke, F, Varela, M, Galle, PR, Alvares-da-Silva, MR, Trojan, J, Bridgewater, J, Cabibbo, G, Toso, C, Lachenmayer, A, Casadei-Gardini, A, Toyoda, H, Lüdde, T, Villani, R, Matilla Peña, AM, Guedes Leal, CR, Ronzoni, M, Delgado, M, Perelló, C, Pascual, S, Lledó, JL, Argemi, J, Basu, B, da Fonseca, L, Acevedo, J, Siebenhüner, AR, Braconi, C, Meyers, BM, Granito, A, Sala, M, Rodríguez-Lope, C, Blaise, L, Romero-Gómez, M, Piñero, F, Gomez, D, Mello, V, Pinheiro Alves, RC, França, A, Branco, F, Brandi, G, Pereira, G, Coll, S, Guarino, M, Benítez, C, Anders, MM, Bandi, JC, Vergara, M, Calvo, M, Peck-Radosavljevic, M, García-Juárez, I, Cardinale, V, Lozano, M, Gambato, M, Okolicsanyi, S, Morales-Arraez, D, Elvevi, A, Muñoz, AE, Lué, A, Iavarone, M & Reig, M 2021, 'Assessing the impact of COVID-19 on liver cancer management (CERO-19)', JHEP Reports, vol. 3, no. 3, 100260. https://doi.org/10.1016/j.jhepr.2021.100260

@article{b8e52cc056424ca8bfd1d11412b42906,

title = "Assessing the impact of COVID-19 on liver cancer management (CERO-19)",

abstract = "Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.",

keywords = "COVID-19, Cholangiocarcinoma, Clinical trials, Hepatocellular carcinoma, Liver cancer, Management, Nurses",

author = "Sergio Mu{\~n}oz-Mart{\'i}nez and Victor Sapena and Alejandro Forner and Nault, {Jean Charles} and Gonzalo Sapisochin and Lorenza Rimassa and Bruno Sangro and Jordi Bruix and Marco Sanduzzi-Zamparelli and Wac{\l}aw Ho{\l}{\'o}wko and {El Kassas}, Mohamed and Tudor Mocan and Mohamed Bouattour and Philippe Merle and Hoogwater, {Frederik J.H.} and Alqahtani, {Saleh A.} and Reeves, {Helen L.} and Pinato, {David J.} and Emmanouil Giorgakis and Tim Meyer and Villadsen, {Gerda Elisabeth} and Henning Wege and Massimiliano Salati and Beatriz M{\'i}nguez and {Di Costanzo}, {Giovan Giuseppe} and Christoph Roderburg and Frank Tacke and Mar{\'i}a Varela and Galle, {Peter R.} and Alvares-da-Silva, {Mario Reis} and J{\"o}rg Trojan and John Bridgewater and Giuseppe Cabibbo and Christian Toso and Anja Lachenmayer and Andrea Casadei-Gardini and Hidenori Toyoda and Tom L{\"u}dde and Rosanna Villani and {Matilla Pe{\~n}a}, {Ana Mar{\'i}a} and {Guedes Leal}, {Cassia Regina} and Monica Ronzoni and Manuel Delgado and Christie Perell{\'o} and Sonia Pascual and Lled{\'o}, {Jos{\'e} Luis} and Josepmaria Argemi and Bristi Basu and {da Fonseca}, Leonardo and Juan Acevedo and Siebenh{\"u}ner, {Alexander R.} and Chiara Braconi and Meyers, {Brandon M.} and Alessandro Granito and Margarita Sala and Carlos Rodr{\'i}guez-Lope and Lorraine Blaise and Manuel Romero-G{\'o}mez and Federico Pi{\~n}ero and Dhanny Gomez and Vivianne Mello and {Pinheiro Alves}, {Rogerio Camargo} and Alex Fran{\c c}a and Fernanda Branco and Giovanni Brandi and Gustavo Pereira and Susanna Coll and Maria Guarino and Carlos Ben{\'i}tez and Anders, {Maria Margarita} and Bandi, {Juan C.} and Mercedes Vergara and Mariona Calvo and Markus Peck-Radosavljevic and Ignacio Garc{\'i}a-Ju{\'a}rez and Vincenzo Cardinale and Mar Lozano and Martina Gambato and Stefano Okolicsanyi and Dalia Morales-Arraez and Alessandra Elvevi and Mu{\~n}oz, {Alberto E.} and Alberto Lu{\'e} and Massimo Iavarone and Maria Reig",

note = "Funding Information: SM.-M.: Speaker fees from Bayer and travel funding from Bayer and Eisai. V.S.: Travel grants from Bayer. A.F.: Lecture fees from Bayer, Gilead and MSD; consultancy fees from Bayer, AstraZeneca, Roche and Guerbert. J-C.N.: Received research grant from Bayer for Inserm UMR1138. L.R.: Reports receiving consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi; lectures fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi; travel fees from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Roche. B.S.: Reports consultancy fees from Adaptimmune, AstraZeneca, Bayer, BMS, BTG, Eli Lilly, Ipsen, Novartis, Merck, Roche, Sirtex Medical, Terumo; and research grants from BMS and Sirtex Medical. J. Bruix: Consultancy: AbbVie, ArQule, Astra, Basilea, Bayer, BMS, Daiichi Sankyo, GlaxoSmithKline, Gilead, Kowa, Lilly, Medimune, Novartis, Onxeo, Polaris, Quirem, Roche, Sanofi-Aventis, Sirtex, Terumo/Grants: Bayer and Ipsen. M.S.Z.: Received speaker fees and travel grants from Bayer and BTG, MSD. M.B.: Consultant and Advisory Board for: Bayer Pharma, Ipsen, BMS, Eisai, Roche, AstraZeneca, Sirtex Medical. D.J.P.: Received lecture fees from ViiV Healthcare and Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, and AstraZeneca; received research funding (to institution) from MSD and BMS. T.M.: Consultancy: Eisai, Roche, BTG, Ipsen, Bayer, Adaptimmune. Research funding: Bayer, BTG. H.W.: Served as speaker for Bayer, Eisai, and Ipsen, and as a consultant for Bayer, Eisai, Lilly, BMS, Roche, and Ipsen. B.M.: Consultancy: Bayer-Shering Pharma /Speaker fees: Eisai, MSDG. C. Consultancy fees from Bayer, Ipsen. P.R.G.: Bayer, BMS, MSD, AstraZeneca, Adaptimmune, Sirtex, Lilly Ipsen, Roche, Eisai. M.R.A.S.: Has received Research grants, advisory board or speaker fees for AbbVie, Bayer, Biolab, Intercept, Ipsen, Gilead, MSD, Novartis, and Roche. J.T.: Has received research grants from Roche and Ipsen. He has received speaker and consulting honoraria from AstraZeneca, Amgen, Bayer Healthcare, Bristol Myers-Squibb, Eisai, Ipsen, Merck Serono, Merck Sharp & Dome, Lilly Imclone, and Roche. J. Bridgewater: Consultancy Bayer, BMS, Incyte, Taiho, Roche, MSD and Merck Serono. Research funding from Incyte. G.C.: Consultancy fees from Bayer, Ipsen. A.L.: Consultancy CAScination, Advisory Board Neuwave and Histosonics. H.T.: Speaker fees from AbbVie, Gilead, MSD, and Bayer. R.V.: Research grant from Abbvie. A.M.M.P.: Speaker honorarium from Bayer, BMS, Boston Scientific and EISAI. Consulting honorarium from Bayer, AstraZeneca and EISAI. Advisory honorarium from Bayer, AstraZeneca and EISAI. Grants from Bayer and Boston Scientific. M.D.: Has received consulting and training fees from Bayer and Eisai. B.B.: Reports Consultancy for GenMab (paid to Institution); Advisory Boards for Roche (paid to Institution), Eisai Europe Limited (paid to Institution), research grant from Celgene Ltd (paid to Institution), Speakers Bureau for Eisai Europe Limited (paid to Institution), Travel and registration for Congress from Bayer. L.d.F.: Lectures fees from BMS, Roche and Bayer. B.M.M.: Advisory/Speaker: Amgen, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Merck, Roche, Sanoffi Genzyme, Taiho. Expert Testimony: Eisai, Roche. Travel: Eisai, Merck. Research: Sillajen (Individual); AstraZeneca, H3/Eisai, Galera, GSK, Exelixis (Institution). M.S.: Travel/ accommodation/meeting expenses: Bayer. Eisai. Speaker fees: Bayer. C.R.L.: Travel grants from Bayer. M.R-G.: Reports grants from Intercept, grants from Gilead-Sciences, personal fees from Shionogi, personal fees from Alfa-Wasserman, personal fees from Prosciento, personal fees from Kaleido, personal fees from Novonrdisk, personal fees from MSD, personal fees from BMS, personal fees from Allergan, personal fees from Boehriger-Ingelheim, personal fees from Zydus, personal fees from Intercept Pharma, personal fees from Gilead-Sciences, outside the submitted work. F.P.: Disclosures: Received speaker honoraria from Bayer, Roche, LKM-Biotoscana, RAFFO. Research Grants from INC Argentinean National Institute of Corrections, Roche. V.M.: Lectures sponsored by Bayer. G.B.: Advisory board Eli-Lilly and Incyte. M. Vergara: Travel grants from Bayer, Gilead, MSD and Abbvie. Lectures sponsored by Gilead, Abbvie, Intercept, and MSD. M.L.: Lectures and educational presentations: Abbvie. Travel/accommodation, meeting expenses covered by Bayer, Gilead, Abbvie. M.I.: Received speaker honoraria from Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, EISAI, and was consultant for BTG-Boston Scientific, Bayer, and Guerbet. M.R.: Consultancy: Bayer-Schering Pharma, BMS, Roche, Ipsen, AstraZeneca, Lilly, BTG/Paid conferences: Bayer-Schering Pharma, BMS, Gilead, Lilly/Research Grants: Bayer-Schering Pharma, Ipsen.S.M.-M. received the grant support “Beca para Perfeccionamiento en Gastroenterolog{\'i}a en el Extranjero” from Asociaci{\'o}n Mexicana de Gastroenterolog{\'i}a, A.C. A.F. received grant support from Instituto de Salud Carlos III (PI13/01229 and PI18/00542). J. Bruix received grant support from Instituto de Salud Carlos III (PI18/00768), AECC (PI044031), and WCR (AICR) 16-0026. M.S.Z. was supported by “Ajuts per a la iniciaci{\'o} a la recerca 2019 from Societat Catalana de Digestologia (SCD)” and received grant support from Instituto de Salud Carlos III (FI19/00222). H.L.R. is supported by funding from Cancer Research UK (CR UK) centre grant C9380/A18084; CR UK programme grant C18342/A23390 and CR UK Accelerator award HUNTER C9380/A26813. D.J.P. is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416) and acknowledges grant support from the Cancer Treatment and Research Trust (CTRT) and infrastructural support by the Cancer Research UK Imperial Centre, the Imperial College Experimental Cancer Medicine Centre (ECMC) and the NIHR Imperial Biomedical Research Centre. B.M. received grant support from Instituto de Salud Carlos III (PI18/00961). J. Bridgewater is in part funded by the UCLH / UCL Biomedical Research Centre. M.S. received funding from CIBEREHD (CB06/04/0033) and AGAUR (2017-SGR-490). M.R. received grant support from Instituto de Salud Carlos III (PI15/00145 and PI18/0358). Some of the authors of this article are members of the European Reference Network (ERN) RARE-LIVER. Some of the authors of this article are members of the European Network for the Study of Cholangiocarcinoma (ENS-CCA).This article/publication is based upon work from COST Action CA18122 European Cholangiocarcinoma Network supported by COST (European Cooperation in Science and Technology) www.cost.eu Funding Information: S.M.-M. received the grant support “Beca para Perfeccionamiento en Gastroenterolog{\'i}a en el Extranjero” from Asociaci{\'o}n Mexicana de Gastroenterolog{\'i}a , A.C. A.F. received grant support from Instituto de Salud Carlos III ( PI13/01229 and PI18/00542 ). J. Bruix received grant support from Instituto de Salud Carlos III ( PI18/00768 ), AECC ( PI044031 ), and WCR (AICR) 16-0026. M.S.Z. was supported by “ Ajuts per a la iniciaci{\'o} a la recerca 2019 from Societat Catalana de Digestologia (SCD) ” and received grant support from Instituto de Salud Carlos III ( FI19/00222 ). H.L.R. is supported by funding from Cancer Research UK (CR UK) centre grant C9380/A18084 ; CR UK programme grant C18342/A23390 and CR UK Accelerator award HUNTER C9380 / A26813 . D.J.P. is supported by grant funding from the Wellcome Trust Strategic Fund ( PS3416 ) and acknowledges grant support from the Cancer Treatment and Research Trust (CTRT) and infrastructural support by the Cancer Research UK Imperial Centre, the Imperial College Experimental Cancer Medicine Centre (ECMC) and the NIHR Imperial Biomedical Research Centre . B.M. received grant support from Instituto de Salud Carlos III ( PI18/00961 ). J. Bridgewater is in part funded by the UCLH / UCL Biomedical Research Centre . M.S. received funding from CIBEREHD ( CB06/04/0033 ) and AGAUR ( 2017-SGR-490 ). M.R. received grant support from Instituto de Salud Carlos III ( PI15/00145 and PI18/0358 ). Funding Information: Some of the authors of this article are members of the European Reference Network (ERN) RARE-LIVER. Some of the authors of this article are members of the European Network for the Study of Cholangiocarcinoma (ENS-CCA).This article/publication is based upon work from COST Action CA18122 European Cholangiocarcinoma Network supported by COST (European Cooperation in Science and Technology) www.cost.eu Publisher Copyright: {\textcopyright} 2021 The Authors",

year = "2021",

month = jun,

doi = "10.1016/j.jhepr.2021.100260",

language = "English (US)",

volume = "3",

journal = "JHEP Reports",

issn = "2589-5559",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Assessing the impact of COVID-19 on liver cancer management (CERO-19)

AU - Muñoz-Martínez, Sergio

AU - Sapena, Victor

AU - Forner, Alejandro

AU - Nault, Jean Charles

AU - Sapisochin, Gonzalo

AU - Rimassa, Lorenza

AU - Sangro, Bruno

AU - Bruix, Jordi

AU - Sanduzzi-Zamparelli, Marco

AU - Hołówko, Wacław

AU - El Kassas, Mohamed

AU - Mocan, Tudor

AU - Bouattour, Mohamed

AU - Merle, Philippe

AU - Hoogwater, Frederik J.H.

AU - Alqahtani, Saleh A.

AU - Reeves, Helen L.

AU - Pinato, David J.

AU - Giorgakis, Emmanouil

AU - Meyer, Tim

AU - Villadsen, Gerda Elisabeth

AU - Wege, Henning

AU - Salati, Massimiliano

AU - Mínguez, Beatriz

AU - Di Costanzo, Giovan Giuseppe

AU - Roderburg, Christoph

AU - Tacke, Frank

AU - Varela, María

AU - Galle, Peter R.

AU - Alvares-da-Silva, Mario Reis

AU - Trojan, Jörg

AU - Bridgewater, John

AU - Cabibbo, Giuseppe

AU - Toso, Christian

AU - Lachenmayer, Anja

AU - Casadei-Gardini, Andrea

AU - Toyoda, Hidenori

AU - Lüdde, Tom

AU - Villani, Rosanna

AU - Matilla Peña, Ana María

AU - Guedes Leal, Cassia Regina

AU - Ronzoni, Monica

AU - Delgado, Manuel

AU - Perelló, Christie

AU - Pascual, Sonia

AU - Lledó, José Luis

AU - Argemi, Josepmaria

AU - Basu, Bristi

AU - da Fonseca, Leonardo

AU - Acevedo, Juan

AU - Siebenhüner, Alexander R.

AU - Braconi, Chiara

AU - Meyers, Brandon M.

AU - Granito, Alessandro

AU - Sala, Margarita

AU - Rodríguez-Lope, Carlos

AU - Blaise, Lorraine

AU - Romero-Gómez, Manuel

AU - Piñero, Federico

AU - Gomez, Dhanny

AU - Mello, Vivianne

AU - Pinheiro Alves, Rogerio Camargo

AU - França, Alex

AU - Branco, Fernanda

AU - Brandi, Giovanni

AU - Pereira, Gustavo

AU - Coll, Susanna

AU - Guarino, Maria

AU - Benítez, Carlos

AU - Anders, Maria Margarita

AU - Bandi, Juan C.

AU - Vergara, Mercedes

AU - Calvo, Mariona

AU - Peck-Radosavljevic, Markus

AU - García-Juárez, Ignacio

AU - Cardinale, Vincenzo

AU - Lozano, Mar

AU - Gambato, Martina

AU - Okolicsanyi, Stefano

AU - Morales-Arraez, Dalia

AU - Elvevi, Alessandra

AU - Muñoz, Alberto E.

AU - Lué, Alberto

AU - Iavarone, Massimo

AU - Reig, Maria

N1 - Funding Information: SM.-M.: Speaker fees from Bayer and travel funding from Bayer and Eisai. V.S.: Travel grants from Bayer. A.F.: Lecture fees from Bayer, Gilead and MSD; consultancy fees from Bayer, AstraZeneca, Roche and Guerbert. J-C.N.: Received research grant from Bayer for Inserm UMR1138. L.R.: Reports receiving consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, Exelixis, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi; lectures fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, Roche, Sanofi; travel fees from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Roche. B.S.: Reports consultancy fees from Adaptimmune, AstraZeneca, Bayer, BMS, BTG, Eli Lilly, Ipsen, Novartis, Merck, Roche, Sirtex Medical, Terumo; and research grants from BMS and Sirtex Medical. J. Bruix: Consultancy: AbbVie, ArQule, Astra, Basilea, Bayer, BMS, Daiichi Sankyo, GlaxoSmithKline, Gilead, Kowa, Lilly, Medimune, Novartis, Onxeo, Polaris, Quirem, Roche, Sanofi-Aventis, Sirtex, Terumo/Grants: Bayer and Ipsen. M.S.Z.: Received speaker fees and travel grants from Bayer and BTG, MSD. M.B.: Consultant and Advisory Board for: Bayer Pharma, Ipsen, BMS, Eisai, Roche, AstraZeneca, Sirtex Medical. D.J.P.: Received lecture fees from ViiV Healthcare and Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, and AstraZeneca; received research funding (to institution) from MSD and BMS. T.M.: Consultancy: Eisai, Roche, BTG, Ipsen, Bayer, Adaptimmune. Research funding: Bayer, BTG. H.W.: Served as speaker for Bayer, Eisai, and Ipsen, and as a consultant for Bayer, Eisai, Lilly, BMS, Roche, and Ipsen. B.M.: Consultancy: Bayer-Shering Pharma /Speaker fees: Eisai, MSDG. C. Consultancy fees from Bayer, Ipsen. P.R.G.: Bayer, BMS, MSD, AstraZeneca, Adaptimmune, Sirtex, Lilly Ipsen, Roche, Eisai. M.R.A.S.: Has received Research grants, advisory board or speaker fees for AbbVie, Bayer, Biolab, Intercept, Ipsen, Gilead, MSD, Novartis, and Roche. J.T.: Has received research grants from Roche and Ipsen. He has received speaker and consulting honoraria from AstraZeneca, Amgen, Bayer Healthcare, Bristol Myers-Squibb, Eisai, Ipsen, Merck Serono, Merck Sharp & Dome, Lilly Imclone, and Roche. J. Bridgewater: Consultancy Bayer, BMS, Incyte, Taiho, Roche, MSD and Merck Serono. Research funding from Incyte. G.C.: Consultancy fees from Bayer, Ipsen. A.L.: Consultancy CAScination, Advisory Board Neuwave and Histosonics. H.T.: Speaker fees from AbbVie, Gilead, MSD, and Bayer. R.V.: Research grant from Abbvie. A.M.M.P.: Speaker honorarium from Bayer, BMS, Boston Scientific and EISAI. Consulting honorarium from Bayer, AstraZeneca and EISAI. Advisory honorarium from Bayer, AstraZeneca and EISAI. Grants from Bayer and Boston Scientific. M.D.: Has received consulting and training fees from Bayer and Eisai. B.B.: Reports Consultancy for GenMab (paid to Institution); Advisory Boards for Roche (paid to Institution), Eisai Europe Limited (paid to Institution), research grant from Celgene Ltd (paid to Institution), Speakers Bureau for Eisai Europe Limited (paid to Institution), Travel and registration for Congress from Bayer. L.d.F.: Lectures fees from BMS, Roche and Bayer. B.M.M.: Advisory/Speaker: Amgen, AstraZeneca, Bayer, BMS, Eisai, Ipsen, Merck, Roche, Sanoffi Genzyme, Taiho. Expert Testimony: Eisai, Roche. Travel: Eisai, Merck. Research: Sillajen (Individual); AstraZeneca, H3/Eisai, Galera, GSK, Exelixis (Institution). M.S.: Travel/ accommodation/meeting expenses: Bayer. Eisai. Speaker fees: Bayer. C.R.L.: Travel grants from Bayer. M.R-G.: Reports grants from Intercept, grants from Gilead-Sciences, personal fees from Shionogi, personal fees from Alfa-Wasserman, personal fees from Prosciento, personal fees from Kaleido, personal fees from Novonrdisk, personal fees from MSD, personal fees from BMS, personal fees from Allergan, personal fees from Boehriger-Ingelheim, personal fees from Zydus, personal fees from Intercept Pharma, personal fees from Gilead-Sciences, outside the submitted work. F.P.: Disclosures: Received speaker honoraria from Bayer, Roche, LKM-Biotoscana, RAFFO. Research Grants from INC Argentinean National Institute of Corrections, Roche. V.M.: Lectures sponsored by Bayer. G.B.: Advisory board Eli-Lilly and Incyte. M. Vergara: Travel grants from Bayer, Gilead, MSD and Abbvie. Lectures sponsored by Gilead, Abbvie, Intercept, and MSD. M.L.: Lectures and educational presentations: Abbvie. Travel/accommodation, meeting expenses covered by Bayer, Gilead, Abbvie. M.I.: Received speaker honoraria from Bayer, Gilead Sciences, BMS, Janssen, Ipsen, MSD, BTG-Boston Scientific, AbbVie, EISAI, and was consultant for BTG-Boston Scientific, Bayer, and Guerbet. M.R.: Consultancy: Bayer-Schering Pharma, BMS, Roche, Ipsen, AstraZeneca, Lilly, BTG/Paid conferences: Bayer-Schering Pharma, BMS, Gilead, Lilly/Research Grants: Bayer-Schering Pharma, Ipsen.S.M.-M. received the grant support “Beca para Perfeccionamiento en Gastroenterología en el Extranjero” from Asociación Mexicana de Gastroenterología, A.C. A.F. received grant support from Instituto de Salud Carlos III (PI13/01229 and PI18/00542). J. Bruix received grant support from Instituto de Salud Carlos III (PI18/00768), AECC (PI044031), and WCR (AICR) 16-0026. M.S.Z. was supported by “Ajuts per a la iniciació a la recerca 2019 from Societat Catalana de Digestologia (SCD)” and received grant support from Instituto de Salud Carlos III (FI19/00222). H.L.R. is supported by funding from Cancer Research UK (CR UK) centre grant C9380/A18084; CR UK programme grant C18342/A23390 and CR UK Accelerator award HUNTER C9380/A26813. D.J.P. is supported by grant funding from the Wellcome Trust Strategic Fund (PS3416) and acknowledges grant support from the Cancer Treatment and Research Trust (CTRT) and infrastructural support by the Cancer Research UK Imperial Centre, the Imperial College Experimental Cancer Medicine Centre (ECMC) and the NIHR Imperial Biomedical Research Centre. B.M. received grant support from Instituto de Salud Carlos III (PI18/00961). J. Bridgewater is in part funded by the UCLH / UCL Biomedical Research Centre. M.S. received funding from CIBEREHD (CB06/04/0033) and AGAUR (2017-SGR-490). M.R. received grant support from Instituto de Salud Carlos III (PI15/00145 and PI18/0358). Some of the authors of this article are members of the European Reference Network (ERN) RARE-LIVER. Some of the authors of this article are members of the European Network for the Study of Cholangiocarcinoma (ENS-CCA).This article/publication is based upon work from COST Action CA18122 European Cholangiocarcinoma Network supported by COST (European Cooperation in Science and Technology) www.cost.eu Funding Information: S.M.-M. received the grant support “Beca para Perfeccionamiento en Gastroenterología en el Extranjero” from Asociación Mexicana de Gastroenterología , A.C. A.F. received grant support from Instituto de Salud Carlos III ( PI13/01229 and PI18/00542 ). J. Bruix received grant support from Instituto de Salud Carlos III ( PI18/00768 ), AECC ( PI044031 ), and WCR (AICR) 16-0026. M.S.Z. was supported by “ Ajuts per a la iniciació a la recerca 2019 from Societat Catalana de Digestologia (SCD) ” and received grant support from Instituto de Salud Carlos III ( FI19/00222 ). H.L.R. is supported by funding from Cancer Research UK (CR UK) centre grant C9380/A18084 ; CR UK programme grant C18342/A23390 and CR UK Accelerator award HUNTER C9380 / A26813 . D.J.P. is supported by grant funding from the Wellcome Trust Strategic Fund ( PS3416 ) and acknowledges grant support from the Cancer Treatment and Research Trust (CTRT) and infrastructural support by the Cancer Research UK Imperial Centre, the Imperial College Experimental Cancer Medicine Centre (ECMC) and the NIHR Imperial Biomedical Research Centre . B.M. received grant support from Instituto de Salud Carlos III ( PI18/00961 ). J. Bridgewater is in part funded by the UCLH / UCL Biomedical Research Centre . M.S. received funding from CIBEREHD ( CB06/04/0033 ) and AGAUR ( 2017-SGR-490 ). M.R. received grant support from Instituto de Salud Carlos III ( PI15/00145 and PI18/0358 ). Funding Information: Some of the authors of this article are members of the European Reference Network (ERN) RARE-LIVER. Some of the authors of this article are members of the European Network for the Study of Cholangiocarcinoma (ENS-CCA).This article/publication is based upon work from COST Action CA18122 European Cholangiocarcinoma Network supported by COST (European Cooperation in Science and Technology) www.cost.eu Publisher Copyright: © 2021 The Authors

PY - 2021/6

Y1 - 2021/6

N2 - Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.

AB - Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.

KW - COVID-19

KW - Cholangiocarcinoma

KW - Clinical trials

KW - Hepatocellular carcinoma

KW - Liver cancer

KW - Management

KW - Nurses

UR - http://www.scopus.com/inward/record.url?scp=85105461585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105461585&partnerID=8YFLogxK

U2 - 10.1016/j.jhepr.2021.100260

DO - 10.1016/j.jhepr.2021.100260

M3 - Article

C2 - 33644725

AN - SCOPUS:85105461585

SN - 2589-5559

VL - 3

JO - JHEP Reports

JF - JHEP Reports

IS - 3

M1 - 100260

ER -

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this